Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.

doi:10.1016/j.ophtha.2012.02.017

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.

Ophthalmology - 1 Aug 2012

Onken Michael D, Worley Lori A, Char Devron H, Augsburger James J, Correa Zelia M, Nudleman Eric, Aaberg Thomas M, Altaweel Michael M, Bardenstein David S, Finger Paul T, Gallie Brenda L, Harocopos George J, Hovland Peter G, McGowan Hugh D, Milman Tatyana, Mruthyunjaya Prithvi, Simpson E Rand, Smith Morton E, Wilson David J, Wirostko William J, Harbour J William

Abstract excerpt

PURPOSE: This study evaluates the prognostic performance of a 15 gene expression profiling (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low metastatic risk) and class 2 (high metastatic risk). DESIGN: Prospective, multicenter study. PARTICIPANTS: A total of 459 patients with posterior uveal melanoma were enrolled from 12 independent centers. TESTING: Tumors were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 3

Share to Follow-Up Studies

Share to Gene Expression Regulation, Neoplastic

Share to Melanoma

Share to Oligonucleotide Array Sequence Analysis

Share to Real-Time Polymerase Chain Reaction

Share to Uveal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 22521086
DOI: 10.1016/j.ophtha.2012.02.017
PMCID: PMC3404209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.PMID 22521086Read ↗

Prognostication of uveal melanoma is simple and highly predictive using The Cancer Genome Atlas (TCGA) classification: A reviewSemantic proximity Read ↗

The Cancer Genome Atlas for uveal melanoma is predictive of patient outcomes.Semantic proximity Read ↗

A molecular revolution in uveal melanoma: implications for patient care and targeted therapy.Semantic proximity Read ↗

Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic DeathSemantic proximity Read ↗

Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanomaSemantic proximity Read ↗

COMPREHENSIVE MOLECULAR PROFILING OF UVEAL MELANOMA EVALUATED WITH GENE EXPRESSION PROFILING, PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA EXPRESSION, AND NEXT-GENERATION SEQUENCING.Semantic proximity Read ↗

Next-Generation Sequencing of Uveal Melanoma for Detection of Genetic Alterations Predicting MetastasisSemantic proximity Read ↗

Transcriptomic versus Chromosomal Prognostic Markers and Clinical Outcome in Uveal MelanomaSemantic proximity Read ↗

Genomic, prognostic, and cell-signaling advances in uveal melanoma.Semantic proximity Read ↗

Prognostic Testing in Uveal Melanoma by Transcriptomic Profiling of Fine Needle Biopsy SpecimensSemantic proximity Read ↗

Gene Expression Profiling in Uveal Melanoma: Two Regions on 3p Related to PrognosisSemantic proximity Read ↗

Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.